Using electrical stimulation to relieve dry mouth in head and neck cancer patients after radiation

Prospective Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck

NA · University of Rochester · NCT04805528

This study is testing if a new electrical therapy can help relieve dry mouth symptoms in head and neck cancer patients who have had radiation treatment.

Quick facts

PhaseNA
Study typeInterventional
Enrollment75 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity of Rochester (other)
Drugs / interventionsradiation
Locations1 site (Rochester, New York)
Trial IDNCT04805528 on ClinicalTrials.gov

What this trial studies

This study aims to evaluate the effectiveness of acupuncture-like electrical therapy, known as ALTENS, in alleviating dry mouth symptoms in patients who have undergone radiation therapy for head and neck cancer. The approach involves applying low-level electrical stimulation to acupuncture points, which may provide similar benefits to traditional acupuncture. Participants will receive ALTENS therapy over a 12-week period, and their progress will be monitored through quality of life questionnaires. The study seeks to determine if this non-invasive method can improve the quality of life for affected patients.

Who should consider this trial

Good fit: Ideal candidates are adults over 18 years old who have received radiation therapy for head and neck cancer and experience dry mouth symptoms.

Not a fit: Patients currently undergoing concurrent chemoradiation therapy or those with unstable cardiac conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve the quality of life for patients suffering from dry mouth after radiation therapy.

How similar studies have performed: Previous studies have indicated that acupuncture can help alleviate dry mouth symptoms, suggesting potential success for this similar approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \> 18 years
* No restrictions on gender or ethnicity
* Ability and willingness to present for ALTENS therapy over 12 weeks
* Previous radiation to the head and neck with a dose \> 50 Gy
* Subjective complaint of dry mouth
* No evidence of active malignancy in the head and neck region
* Minimum of 3 months post initial curative therapy with no evidence of active disease by standard of care surveillance scans for said disease site

Exclusion Criteria:

* Age under 18 years of age
* Inability to present for ALTENS therapy
* Inability to fill out quality of life questionnaires
* Ability and desire to receive concurrent chemoradiation therapy
* Because ALTENs may stimulate nerves similar to those of pilocarpine, the following exclusions are noted as theoretically ALTENS could produce worse symptoms

  * Unstable Angina
  * Unstable cardiac disease with hospitalization in the last 6 months
  * Presence of a pacemaker, ICD, or other electronic implanted device that could be affected
  * Myocardial infarction in the last 6 months
  * Symptomatic arrhythmia in the last 6 months
  * Severe COPD with exacerbation causing hospitalization within the last 6 months
* Pregnancy or the possibility of pregnancy

Where this trial is running

Rochester, New York

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Head and Neck Cancer, Acupuncture-Like Transcutaneous Electrical Stimulation, dry mouth

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.